[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

+41-61-324-1111

Condition

Acute Gout

Treatment type

Interventional

Investigational product

ACZ885

Phase

Phase 3

Sponsor

Novartis

ClinicalTrials.gov identifier

NCT01194921

Study number

CACZ885H2357E2

Date first posted

September 2, 2010

Date last update

April 27, 2012

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

The purpose of this second extension study is to collect long-term safety and tolerability data and additional efficacy data in patients who are treated on demand upon flare with canakinumab.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria
Exclusion criteria
  1. Continuation in this extension study is considered inappropriate by the treating physician
  2. Pregnant or nursing (lactating) women
  3. Female patients being physiologically capable of becoming pregnant UNLESS they are using an acceptable method of contraception with a failure rate (Pearl Index (PI)) < 1 Other protocol defined inclusion/exclusion criteria may apply.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site